Description
US medical device companies outsource 40% of their clinical trials and that number is expected to increase. Given this trend, it is essential that both industry and the regulator understand the nature of their symbiotic relationships. This session will cover strategies that may strengthen their relationship as well as pitfalls that may weaken it.
Speaker(s):
